Tiziana Life Sciences PLC (LON:TILS – Get Rating) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 58.50 ($0.71) and traded as low as GBX 45 ($0.55). Tiziana Life Sciences shares last traded at GBX 58.50 ($0.71), with a volume of 297,127 shares traded.
Tiziana Life Sciences Trading Up 8.3 %
The firm’s 50-day simple moving average is GBX 58.50 and its 200 day simple moving average is GBX 58.50. The firm has a market cap of £113.85 million and a P/E ratio of -3.59. The company has a quick ratio of 6.41, a current ratio of 6.54 and a debt-to-equity ratio of 2.36.
About Tiziana Life Sciences
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.